Tadalafil versus Tamsulosin for managing symptomatic benign prostate hypertrophy.

Not Applicable

Recruiting

• Conditions: Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptomsHealth Condition 2: null- Lower urinary tract symptoms(LUTS),Benign Prostatic Hypertrophy (BPH)

• Registration Number: CTRI/2018/03/012825
• Lead Sponsor: niversity College of Medical Sciences University of Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients aged >= 45 years upto 80 years giving informed consent to participate in the study.

2. Patients with clinical symptoms of BPH without absolute and or any urgent indication for surgery.

3. Symptomatic patients with enlarged prostate gland documented with either clinical examination or by ultrasound.

4. Patients without clinical or investigatory evidence of UTI.

5. Patients newly diagnosed with BPH .

6. Patients with diagnosed BPH but not on any medication or stopped medications for the past 2 weeks.

7. Patients of BPH with IPSS Score >7.

Exclusion Criteria

1. Patients with mental disorders or illness who cannot understand or comply with the study protocol.

2. Patients of BPH with secondary complications due to BPH (like CRF, hydronephrosis, acute bacterial prostatitis, hematuria).

3. Patients with LUTS/BOO due to causes other than BPH (neurogenic causes).

4. Patients with known drug allergy/contraindications to tamsulosin/ tadalafil.

5. Patients taking nitrates for angina pectoris, CYP3A4 inhibitors (ketoconazole, ritonavir) and CYP3A4 inducers (rifampin).

6. Patients with previous history of prostate surgery.

7. Cancer prostate

Study & Design

• Study Type: Interventional
• Study Design: Not specified